Evidence map›Paper›PMID 25594159›Full record

ArticleBlood cancer journal2015

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.

S Atrash, A Tullos, S Panozzo, M Bhutani, F Van Rhee, B Barlogie, S Z Usmani

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Observational
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

S AtrashMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
A TullosMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
S PanozzoMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
M BhutaniLevine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
F Van RheeMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
B BarlogieMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
S Z UsmaniLevine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
University of Arkansas for Medical Sciences · USCarolinas Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug-Related Side Effects and Adverse ReactionsHeart DiseasesHumansMultiple MyelomaNeoplasm Recurrence, LocalOligopeptidescarfilzomibOligopeptides

Identifiers

PMID25594159
PMCPMC4314456
OpenAlexW2001786657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.